FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause

Listen to an audio podcast of the September 12th, 2024 FDA Drug Safety Communication on rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause.
Source: FDA Drug Safety Podcasts

Leave a Comment





This site uses Akismet to reduce spam. Learn how your comment data is processed.